Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Institut Bergonié
City of Hope Medical Center
Bayer
University of California, Irvine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNICANCER
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bayer
National Institutes of Health Clinical Center (CC)
Sarcoma Alliance for Research through Collaboration
M.D. Anderson Cancer Center
British Columbia Cancer Agency
Institut Bergonié
University of Pittsburgh
Telix Pharmaceuticals (Innovations) Pty Limited
University of California, Irvine
Instituto do Cancer do Estado de São Paulo
Elevation Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gustave Roussy, Cancer Campus, Grand Paris
Charite University, Berlin, Germany
pharmaand GmbH
Translational Research in Oncology
Istituto Clinico Humanitas
Novartis
Amgen
Cambridge University Hospitals NHS Foundation Trust
Assaf-Harofeh Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Health Research Institutes, Taiwan
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC